Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Apr 18;148:106564. doi: 10.1016/j.ypmed.2021.106564

Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada

Thomas N Vilches a, Shokoofeh Nourbakhsh b, Kevin Zhang c,, Lyndon Juden-Kelly b, Lauren E Cipriano d, Joanne M Langley e, Pratha Sah f, Alison P Galvani f, Seyed M Moghadas b
PMCID: PMC8053216  PMID: 33878351

Abstract

The novel coronavirus disease 2019 (COVID-19) has caused severe outbreaks in Canadian long-term care facilities (LTCFs). In Canada, over 80% of COVID-19 deaths during the first pandemic wave occurred in LTCFs. We sought to evaluate the effect of mitigation measures in LTCFs including frequent testing of staff, and vaccination of staff and residents. We developed an agent-based transmission model and parameterized it with disease-specific estimates, temporal sensitivity of nasopharyngeal and saliva testing, results of vaccine efficacy trials, and data from initial COVID-19 outbreaks in LTCFs in Ontario, Canada. Characteristics of staff and residents, including contact patterns, were integrated into the model with age-dependent risk of hospitalization and death. Estimates of infection and outcomes were obtained and 95% credible intervals were generated using a bias-corrected and accelerated bootstrap method. Weekly routine testing of staff with 2-day turnaround time reduced infections among residents by at least 25.9% (95% CrI: 23.3%–28.3%), compared to baseline measures of mask-wearing, symptom screening, and staff cohorting alone. A similar reduction of hospitalizations and deaths was achieved in residents. Vaccination averted 2–4 times more infections in both staff and residents as compared to routine testing, and markedly reduced hospitalizations and deaths among residents by 95.9% (95% CrI: 95.4%–96.3%) and 95.8% (95% CrI: 95.5%–96.1%), respectively, over 200 days from the start of vaccination. Vaccination could have a substantial impact on mitigating disease burden among residents, but may not eliminate the need for other measures before population-level control of COVID-19 is achieved.

Keywords: COVID-19, Long-term care, Testing, Vaccination, Agent-based simulations

1. Introduction

The novel coronavirus disease 2019 (COVID-19) has led to severe outbreaks in Canadian long-term care facilities (LTCFs). LTCF residents are particularly vulnerable to COVID-19 due to a high prevalence of comorbid conditions (Ontario Long Term Care Association, 2019) and their advanced age. Since the start of the COVID-19 pandemic, a number of strategies have been implemented to prevent infection and disease transmission in LTCFs, including non-pharmacological measures such as isolation, visitor restrictions, hand hygiene, and mask-wearing (Centers for Disease Control and Prevention, 2020; Wang et al., 2020b). While COVID-19 mitigation measures have had a significant impact on reducing transmission on a population level (Zhang et al., 2020), control of outbreaks in LTCFs has proved to be challenging, in part due to silent transmission from infected asymptomatic or presymptomatic visitors and staff (Ladhani et al., 2020; Ouslander and Grabowski, 2020).

In Canada, over 80% of reported COVID-19 deaths during the first wave were among residents of LTCFs (Barnett and Grabowski, 2020; Canadian Institute for Health Information, 2020; Hsu et al., 2020; Webster, 2021). While advanced age and comorbid medical conditions are risk factors for a more severe course of disease among residents (Garnier-Crussard et al., 2020; Wang et al., 2020a; Yang et al., 2020), recent studies have highlighted the inadequacy of the systemic response to COVID-19 in Canadian LTCFs (Brown et al., 2020; Liu et al., 2020; Stall et al., 2020). Shortages of staff and personal protective equipment (PPE), limited testing capacity with reliance on symptom-based screening, and inadequate space to implement efficient cohorting measures appear to have contributed to the extraordinary disease toll in these settings (Liu et al., 2020). Results from phase III clinical trials of COVID-19 vaccines, as well as their effectiveness in mass immunization campaigns indicate that prioritizing residents and staff for vaccination could prevent LTCF outbreaks (Baden et al., 2020; Dagan et al., 2021; Lipsitch and Kahn, 2021; Polack et al., 2020). However, whether vaccination alone is sufficient to protect these vulnerable populations from COVID-19 remains undetermined. Furthermore, the effectiveness of infection control measures in LTCFs depend on a number of factors such as the contact network between residents and staff, in addition to disease characteristics, such as the presence of symptoms and severity of illness at the individual level.

We sought to investigate the impact of various COVID-19 mitigation measures in LTCFs by developing an agent-based model of disease transmission dynamics. We parameterized the model with disease-specific estimates and data from initial outbreaks in LTCFs in the province of Ontario, Canada (Public Health Ontario, 2020). We also used movement and contact network data collected from the largest veterans care facility in Canada, located at Sunnybrook Health Sciences Centre (Champredon et al., 2018; Najafi et al., 2017). We evaluated the effect of case isolation, mask-wearing, cohorting and routine testing of staff in the absence of vaccination. We then expanded the model to include vaccination and evaluate the need for other interventions.

2. Methods

2.1. Ethics statement

The study was approved by the York University Ethics Review Board (Project: 2020-269). The study was categorized as minimal risk, with no requirement for individual consent or participation.

2.2. Model structure and population

We developed an agent-based simulation model of COVID-19 transmission dynamics in a LTCF with resident and staff populations (Appendix, Fig. A1). The model structure was informed by population demographics of LTCFs in Ontario, Canada, including age (Ontario Long Term Care Association, 2019; Statistics Canada, 2020), staff-to-resident ratios, distribution of rooms, and occupancy (Stall et al., 2020). The interactions within and between staff and resident populations were parameterized using the distributions derived from close-range movement and contact network data collected through wearable sociometric tags in a Canadian LTCF (Najafi et al., 2017). The model included three working shifts of morning, evening, and night, each covering 8 h of daily interactions.

Based on demographic data from the Ontario Long Term Care Association (Ontario Long Term Care Association, 2019), the resident population included individuals aged 50–64 (6.6%), 65–74 (11.4%), 75–84 (27.3%), 85–94 (43.9%), and 95+ (10.8%). A total of 120 residents (i.e., the average size of a LTCF) were included in the model and assigned to 84 rooms, with a distribution corresponding to 48 single and 36 double occupancy rooms. The model considered a daily staff population of 68 individuals, aged 20–64 years (Statistics Canada, 2020), which included direct care providers (i.e., personal support workers, nurses), dietary staff and housekeeping personnel. The distribution of staff by classification and staff-to-resident ratios for each daily shift were informed by correspondence with the management teams of 10 LTFCs affected by COVID-19 outbreaks in Ontario. The overall number of staff varied in the model, depending on substitution that occurred for identified staff with infection.

Daily contacts among residents were sampled from a previously inferred distribution with a mean of 6.8 contacts per resident per day (Champredon et al., 2018; Najafi et al., 2017). Daily numbers of contacts varied from 6 to 9 between residents and direct care providers (nurses and personal support workers). Due to outbreak measures implemented in LTCFs, the model was parameterized with limited contacts between residents and other service staff based on correspondence with the management teams of LTFCs (Appendix, Table A1). Given visiting restrictions during outbreaks, we did not include visitors in the model. Contacts among staff were distributed in each shift depending on the responsibility of staff in the LTCF (Appendix, Table A1).

2.3. Disease dynamics

We encapsulated the natural history of COVID-19 with epidemiological statuses as susceptible; latently infected (not yet infectious); asymptomatic (and infectious); pre-symptomatic (and infectious); symptomatic with either mild or severe/critical illness; recovered; and dead (Fig. 1 ). We assumed that infection was introduced into the LTCF through infected staff during the silent asymptomatic or pre-symptomatic stages of disease. A population point-prevalence of SARS-CoV-2 infection in the range of 0.05%–0.1% was considered for infection of staff outside the LTCF prior to the start of each shift (Defence Research and Development Canada, 2020). Staff with symptomatic COVID-19, whether infected outside or during the daily shifts in the LTCF, were screened and removed from the model simulations for a minimum of 14 days (and until complete recovery). Substitute staff were considered in the model to assume responsibilities of the infected staff during their isolation period.

Fig. 1.

Fig. 1

Incidence of infection per 1000 residents (A,D), cumulative infections per 1000 residents (B,E), and relative reduction of cumulative infections (attack rate), hospitalizations, and deaths with routine testing of staff (C) and vaccination of residents and staff (F), over a 200-day time period of simulations. Intervention scenarios (in addition to baseline control measures) included: weekly routine testing of staff with NP sampling and 1-day (S1a) and 2-day (S1b) turnaround; saliva sampling with 1-day (S2a) and 2-day (S2b) turnaround; and vaccination (S3).

Disease transmission inside the LTCF was implemented probabilistically for contacts between susceptible and infectious individuals in asymptomatic, pre-symptomatic, or symptomatic stages of the disease. Infected individuals started in the latent (non-infectious) stage, and then proceeded to a silent infectious stage (i.e., either asymptomatic or pre-symptomatic). A proportion of infected individuals remained asymptomatic until recovery (Buitrago-Garcia et al., 2020; DeBiasi and Delaney, 2020; Li et al., 2020b; Poline et al., 2020), with an infectious period that was sampled from a Gamma distribution with a mean of 5 days (Gatto et al., 2020; Li et al., 2020a). Others developed symptoms following a pre-symptomatic stage as part of the incubation period. The incubation and pre-symptomatic periods were sampled from Log-Normal and Gamma distributions with mean values of 5.2 and 2.3 days, respectively (He et al., 2020; Lauer et al., 2020). The infectious period post-symptom onset was also sampled from a Gamma distribution with a mean of 3.2 days (Li et al., 2020a). Symptomatic cases had an age-dependent probability of developing mild or severe/critical illness. We assumed that recovery from a primary infection provided adequate immunity for the remainder of the simulation, preventing re-infection. Compared to the probability of transmission during the pre-symptomatic stage, the relative risks were 0.26, 0.44, and 0.89 for the asymptomatic, mild symptomatic, and severe symptomatic stages, respectively (Ferretti et al., 2020; Moghadas et al., 2020a; Sayampanathan et al., 2021).

2.4. Infection outcomes

Residents with symptomatic disease and their roommates, based on outbreak guidelines, were immediately isolated upon symptom onset within the LTCF (Ministry of Health, 2020). Contacts of isolated cases were limited to only direct healthcare providers. A proportion of symptomatic residents who developed severe illness were transferred and hospitalized, and therefore excluded from the dynamics within the LTCF until their return upon recovery. For those who were hospitalized, the time from symptom onset to admission was sampled in the range of 2–5 days (Moghadas et al., 2020b; Shoukat et al., 2020). The length of hospital stay was sampled from a Gamma distribution with mean of 12.4 days (Sanche et al., 2020). We parameterized the model with age-specific hospitalization rates of LTCF residents from January to June 2020 (Table 1 ). The case fatality rate among residents was age-dependent and based on data reported by Public Health Ontario (Table 1) (Public Health Ontario, 2020).

Table 1.

Model parameters and their estimated value.

Model parameter Staff Resident Source
Age group 20–49 50–64 <60 60–69 70–79 80–89 90+
Transmission probability per contact during pre-symptomatic stage 0.0438 (Public Health Ontario, 2020)
Calibrated to incidence data for LTCFs in Ontario
Incubation period (days) Log-Normal(shape: 1.434, scale: 0.661) (Lauer et al., 2020)
Asymptomatic period (days) Gamma(shape: 5, scale: 1) Derived from (Gatto et al., 2020; He et al., 2020)
Pre-symptomatic period (days) Gamma(shape: 1.058, scale: 2.174) (He et al., 2020)
Infectious period from onset of symptoms (days) Gamma(shape: 2.768, scale: 1.1563) Derived from (Li et al., 2020a)
Proportion of individuals with comorbidities 0.18 0.38 1 (Adams et al., 2020; Ontario Long Term Care Association, 2019)
Proportion of infected individuals developing asymptomatic infection 0.328 0.328 0.328 0.258 0.188 0.188 0.188 (Mizumoto et al., 2020)
Proportion of symptomatic cases developing severe illness 0.15 0.40 0.8 (Moghadas et al., 2020b)
Hospitalization rate of symptomatic cases 23.5% 23.5% 18.2% 15.1% 13.4% 9.3% 7.1% (Public Health Ontario, 2020)
Case fatality rate 0.21% 0.21% 8.4% 18.8% 24.1% 27.9% 35.4% (Public Health Ontario, 2020)
Length of hospital stay Gamma(shape: 4.5, scale: 2.75) (Sanche et al., 2020)

2.5. Interventions

The baseline scenario of control measures included: (i) isolation of symptomatic residents with hospitalization of a proportion who developed severe illness; (ii) screening of staff for symptomatic illness followed by isolation; (iii) cohorting of care providers; and (iv) mask-wearing by all staff. We assumed that all staff wore surgical masks during their shift, but switched to an N95 respirator when caring for isolated residents. A recent meta-analysis indicates a 67% (95% CI: 39%–83%) risk reduction in respiratory infections when surgical masks are used (Chu et al., 2020). Thus, the transmission probability per contact was reduced by a factor (1- effsur) for staff-resident, and (1- effsur)2 for staff-staff interactions. When an N95 was used by staff caring for isolated residents, the probability of transmission was reduced by (1-effN95) per contact, with an efficacy effN95 = 0.95 (Chu et al., 2020). For staff cohorting, we assigned each healthcare provider to a specific group of residents. Personal support workers only interacted with a predetermined group of 9, 9, and 20 residents during the three daily shifts of morning, evening, and night. Similarly, nurses interacted with predetermined groups of 30, 30, and 60 residents during the corresponding shifts. Given these baseline interventions, we compared two additional measures: routine testing of all staff and vaccination of staff and residents.

2.5.1. Routine testing

To prevent disease importation and transmission during the silent asymptomatic or pre-symptomatic stages of infection, we implemented routine nasopharyngeal (NP) and saliva PCR testing of staff with a frequency of 7 days (Iacobucci, 2020). The probability of case detection at the time of testing post-infection was determined by the temporal diagnostic sensitivity (Zhang et al., 2021) inferred from fitting a sensitivity function to the percent positivity data of NP testing (Miller et al., 2020). Both tests were assumed to have a specificity of 100%. We considered time delays of 24–48 h in turnaround time from sampling to results, during which staff continued their shifts. Staff isolated for a period of 14 days following a positive result, during which they were excluded from interactions in the LTCF, and substitutes were included.

2.5.2. Vaccination

Considering LTCFs as one of the priority groups for COVID-19 vaccination, we implemented a two-dose vaccine strategy, with coverages of 70% for staff and 90% for residents (Government of Canada, 2021). We reviewed and extracted estimates of efficacy for Moderna vaccines following 2 doses, administered 28 days apart (Baden et al., 2020; U.S. Food and Drug Administration, 2020). We implemented a 14-day interval after the first dose of vaccine during which there was no statistically significant difference between the protection in the vaccinated and unvaccinated cohorts (Appendix, Table A2). Clinical trials indicated that vaccines were highly effective in individuals with predisposing medical conditions that put them at risk for severe Covid-19 (Baden et al., 2020). As sensitivity analyses, we also considered a scenario in which vaccine efficacies were reduced by a factor of q in vaccinated residents, where q was sampled uniformly from the 10%–50% range based on observed reductions in influenza vaccine effectiveness among frail and comorbid individuals (Andrew et al., 2017; Dhakal and Klein, 2019). The results of the sensitivity analysis are presented in Fig. A3 of the Appendix.

2.6. Model implementation and calibration

The model was implemented in Julia language using parameter estimates in Table 1. To determine the transmission probability, we calibrated the model to the cumulative incidence data reported for LTCFs in Ontario, Canada, from January to June 2020 (Public Health Ontario, 2020). For this calibration, we considered case isolation and hospitalization of infected residents, screening of staff for symptomatic illness, and mask-wearing by all staff as measures implemented during initial outbreaks of COVID-19. In the scenario with vaccination, we assumed that the first dose of vaccine was given two weeks before the introduction of the first infection into the LTCF, which resulted in partial effectiveness of vaccination when the outbreak simulations began. The second dose was offered two weeks after the start of simulations. Simulations were seeded with one infected individual among staff with a time-step of 1 h. The computational model is available at https://github.com/thomasvilches/LTCF-covid.

3. Results

In the baseline scenario of model calibration, the attack rate was 24.9% (95% CrI: 24.4–25.4) among residents, and 10.6% (95% CrI: 10.3–10.8) among staff over a 200-day time horizon. Hospitalizations and deaths among residents were projected to be 21.1 (95% CrI: 20.6–21.8) and 52.2 (95% CrI: 51.0–53.4) per 1000 population, respectively, over the same time horizon. The corresponding rates for staff were 2.8 (95% CrI: 2.6–3.0) and 0.35 (95% CrI: 0.28–0.43) per 1000 population.

3.1. Routine testing of staff

Compared to baseline measures only, the addition of weekly routine testing of staff reduced the attack rate among residents by 25.9% (95% CrI: 23.3%–28.3%) using saliva sampling with a 2-day turnaround. The highest reduction was 42.1% (95% CrI: 40.3%–43.9%) using weekly NP sampling with a 1-day turnaround time (Fig. 1C, Table 2 ). For each scenario, the observed reductions of attack rates among staff were similar to those among residents (Table 2).

Table 2.

Mean and 95% credible intervals for the reduction of cumulative infections, hospitalizations, and deaths among residents achieved by additional measures of 7-day routine testing of staff and vaccination of staff and residents, as compared with baseline measures alone, over a 200-day time horizon.

Measure
Mean relative reduction (%) and 95% CrI
7-day routine testing Infection Hospitalization Death
NP sampling 1-day turnaround 42.1 (40.3, 43.9) 42.4 (39.7, 45.2) 43.2 (41.3, 45.4)
2-day turnaround 30.3 (28.4, 32.3) 29.9 (26.6, 33.0) 31.0 (28.9, 33.2)
Saliva sampling 1-day turnaround 34.3 (32.2, 36.2) 34.4 (31.1, 37.1) 34.6 (32.4, 36.9)
2-day turnaround 25.9 (23.3, 28.3) 23.9 (20.4, 27.1) 26.1 (23.5, 28.6)
Vaccination 88.5 (88.1, 88.9) 95.9 (95.4, 96.3) 95.8 (95.5, 96.1)

Weekly routine testing of staff led to a similar reduction of hospitalizations among residents, ranging from 23.9% (95% CrI: 20.4%–27.1%) to 42.4% (95% CrI: 39.7%–45.2%) with a 2-day turnaround for saliva testing and a 1-day turnaround for NP testing, respectively (Fig. 1C, Table 2). The corresponding reductions in deaths among residents ranged from 26.1% (95% CrI: 23.5%–28.6%) to 43.2% (95% CrI: 41.3%–45.4%). We observed similar reductions of hospitalizations and deaths among staff (Table 3 ).

Table 3.

Mean and 95% credible intervals for the reduction of cumulative infections, hospitalizations, and deaths among staff achieved by additional measures of 7-day routine testing of staff and vaccination of staff and residents, as compared with baseline measures alone, over a 200-day time horizon.

Measure
Mean relative reduction (%) and 95% CrI
7-day routine testing Infection Hospitalization Death
NP sampling 1-day turnaround 41.5 (39.3, 43.8) 38.6 (31.9, 45.0) 45.4 (24.4, 59.9)
2-day turnaround 29.5 (27.2, 31.7) 25.3 (17.2, 31.9) 24.4 (0.01, 43.3)
Saliva sampling 1-day turnaround 33.4 (31.0, 35.5) 28.4 (23.0, 36.8) 28.8 (0.1, 46.4)
2-day turnaround 25.3 (22.6, 28.1) 26.2 (16.9, 33.8) 20.5 (−0.04, 37.7)
Vaccination 88.9 (88.4, 89.4) 87.8 (84.3, 90.6) 89.7 (83.5, 95.9)

3.2. Vaccination of residents and staff

When vaccination was implemented, the incidence among residents sharply declined after 4 weeks (Fig. 1D), as compared with baseline measures alone. The attack rate was reduced by 88.5% (95% CrI: 88.1%–88.9%) among residents and 88.9% (95% CrI: 88.4%–89.4%) among staff over a 200-day time horizon (Table 2, Table 3), significantly higher than reductions achieved in any scenario of routine testing in both populations (Wilcoxon rank-sum test, p-values < 0.001). Vaccination reduced hospitalizations and deaths among residents by 95.9% (95% CrI: 95.4%–96.3%) and 95.8% (95% CrI: 95.5%–96.1%); the corresponding reductions in staff were 87.8% (95% CrI: 84.3%–90.6%) and 89.7% (95% CrI: 83.5%–95.9%) (Fig. 1F, Table 2, Table 3).

4. Discussion

The COVID-19 pandemic has disproportionately affected geriatric populations and residents of LTCFs with devastating outcomes (Barnett and Grabowski, 2020; Bell et al., 2020; Burton et al., 2020; Canadian Institute for Health Information, 2020; ECDC Public Health Emergency Team et al., 2020). The incidence rate ratio for COVID-19 related deaths among LTCF residents in Ontario, Canada has been estimated to be 13 times higher than that among adults older than 69 years in community dwellings (Fisman et al., 2020), with case fatality rates exceeding 27% (Brown et al., 2020) during the first pandemic wave. In the absence of vaccination, the control of COVID-19 outbreaks in these vulnerable settings has proved to be challenging largely due to staff shortages and frequent staff turnover, low staff-to-resident ratios, crowded settings without room to implement physical distancing, insufficient training, as well as silent transmission of disease. Furthermore, reliance on symptom-based screening can allow introduction of COVID-19 in LTCFs by asymptomatic, or even mild symptomatic staff which may result in widespread transmission.

Our evaluation of multi-pronged strategies in LTCFs indicate that augmenting non-pharmaceutical measures with routine testing of staff can reduce the rates of silent transmission and would decrease infections and adverse clinical outcomes considerably among residents. We found that with a 2-day or longer time-delay from sample collection to results, the impact of this measure on reducing hospitalizations and deaths among residents was decreased by at least 12% and 8% compared to a 1-day turnaround time in NP and saliva testing, respectively, over a 200-day time horizon (Fig. 1C, Table 2). We observed similar effects of a time-delay in routine testing of staff on cumulative infections among residents (Fig. 1B, Table 2). Vaccination would significantly (2–4 times more than routine testing of staff) reduce infection and severe outcomes among both residents and staff. While vaccines reduce the incidence of infection and may decrease transmission, the practice of other measures (i.e., mask-wearing, social distancing, hand hygiene) will still be needed for some time until community transmission is controlled. Encouragingly, in the province of Ontario, these non-pharmaceutical measures have remained in place despite vaccination of the majority of residents and staff.

4.1. Strengths and limitations

A key strength of our dynamic transmission model is the integration of several interventions implemented in LTCFs (i.e., mask-wearing, symptom-based screening, staff cohorting, isolation, routine testing, and vaccination) and evaluation of their effectiveness in controlling outbreaks in the context of the COVID-19 pandemic. We also utilized interaction data collected using sociometric devices in a real setting (Champredon et al., 2018; Najafi et al., 2017) to parameterize the contact patterns in the model, as well as observed contacts between individuals during LTCF outbreaks in Ontario, Canada. However, our results should be interpreted within study assumptions and limitations. For the model structure, staff-to-resident ratios, and population interactions, we relied on existing data and correspondence with LTCFs affected by COVID-19 in Ontario, Canada. We did not include visitation by community members in the model during the outbreak, which may be allowed with specific guidelines for visitors. We also did not include other modes of disease transmission such as aerosolization of the virus without adequate ventilation. For evaluation of routine testing, we assumed a 100% compliance rate among staff. While this may be a reasonable assumption for non-invasive, self-administered saliva testing, compliance will likely be affected by practical challenges of relatively invasive NP testing. We also assumed that two doses of vaccine were administered according to an interval of one month apart; lower efficacy could be associated with schedules where the rollout of vaccines is delayed. Finally, we assumed that staff cohorting can be effectively and sustainably implemented as described; however, staff shortages and the use of overtime to replace staff may affect the effectiveness of this strategy.

5. Conclusions

Our study highlights the importance of multifaceted strategies, including non-pharmaceutical measures and vaccination, for protecting vulnerable residents in LTCFs. Without population-level control of disease, the risk of infection and silent transmission by staff or visitors in these settings cannot be discounted even with a highly efficacious vaccine.

Funding/support

SMM was supported by the Canadian Institutes of Health Research (OV4 — 170643); Natural Sciences and Engineering Research Council of Canada; and the Canadian Foundation for Innovation. APG was supported by the National Science Foundation (RAPID - 2027755), and the National Institutes of Health (1RO1AI151176-01). TNV was supported by the São Paulo Research Foundation (FAPESP grant 2018/24811-1). LEC was supported by the Society for Medical Decision Making COVID-19 Decision Modeling Initiative funded by the Gordon and Betty Moore Foundation through Grant GBMF9634 to Johns Hopkins University and a Western University Catalyst Research Grant. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author contributions

SMM, LEC, APG, and JML were responsible for conception and design. TNV and SN developed the model and performed simulations. SMM and KZ analyzed the data and drafted the results. LJK and PS parameterized the model and contributed to collection of data and resources. All authors contributed to writing, interpreting the results, and revising the manuscript for accuracy of its content. SMM is the guarantor.

Additional contributions

The authors thank the management teams of LTCFs in Ontario, Canada for helpful conversations that informed our analysis, strategies, and assumptions.

Declaration of Competing Interests

Dr. Joanne M. Langley reports that her institution has received funding for research studies from Sanofi Pasteur, GlaxoSmithKline, Merck, Janssen and Pfizer. Dr. Joanne M. Langley also holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. Other authors declare no competing interests.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ypmed.2021.106564.

Appendix A. Supplementary data

Supplementary material

mmc1.pdf (329.8KB, pdf)

References

  1. Adams M.L., Katz D.L., Grandpre J. Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg. Infect. Dis. 2020;26:1831–1833. doi: 10.3201/eid2608.200679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andrew M.K., Shinde V., Ye L., Hatchette T., Haguinet F., Dos Santos G., McElhaney J.E., Ambrose A., Boivin G., Bowie W., Chit A., ElSherif M., Green K., Halperin S., Ibarguchi B., Johnstone J., Katz K., Langley J., Leblanc J., Loeb M., MacKinnon-Cameron D., McCarthy A., McGeer A., Powis J., Richardson D., Semret M., Stiver G., Trottier S., Valiquette L., Webster D., McNeil S.A., for the Serious Outcomes Surveillance Network of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) and the Toronto Invasive Bacterial Diseases Network (TIBDN) The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people. J. Infect. Dis. 2017;216:405–414. doi: 10.1093/infdis/jix282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., McGettigan J., Khetan S., Segall N., Solis J., Brosz A., Fierro C., Schwartz H., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Mascola J., Polakowski L., Ledgerwood J., Graham B.S., Bennett H., Pajon R., Knightly C., Leav B., Deng W., Zhou H., Han S., Ivarsson M., Miller J., Zaks T. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2035389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnett M.L., Grabowski D.C. Nursing homes are ground zero for COVID-19 pandemic. JAMA Health Forum. 2020;1 doi: 10.1001/jamahealthforum.2020.0369. [DOI] [PubMed] [Google Scholar]
  5. Bell D., Comas-Herrera A., Henderson D., Jones S., Lemmon E., Moro M., Murphy S., O’Reilly D., Patrignani P. International Long-Term Care Policy Network, CPEC-LSE, August 2020. 2020. COVID-19 mortality and long term care: a UK comparison. Article in LTCcovid.org. [Google Scholar]
  6. Brown K.A., Jones A., Daneman N., Chan A.K., Schwartz K.L., Garber G.E., Costa A.P., Stall N.M. Association between nursing home crowding and COVID-19 infection and mortality in Ontario, Canada. JAMA Intern. Med. 2020 doi: 10.1001/jamainternmed.2020.6466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Buitrago-Garcia D., Egli-Gany D., Counotte M.J., Hossmann S., Imeri H., Ipekci A.M., Salanti G., Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLOS Med. 2020;17 doi: 10.1371/journal.pmed.1003346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burton J.K., Bayne G., Evans C., Garbe F., Gorman D., Honhold N., McCormick D., Othieno R., Stevenson J.E., Swietlik S., Templeton K.E., Tranter M., Willocks L., Guthrie B. Evolution and effects of COVID-19 outbreaks in care homes: a population analysis in 189 care homes in one geographical region of the UK. Lancet Healthy Longev. 2020;1:e21–e31. doi: 10.1016/S2666-7568(20)30012-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Canadian Institute for Health Information . 2020. Pandemic Experience in the Long-Term Care Sector: How Does Canada Compare With Other Countries? [Google Scholar]
  10. Centers for Disease Control and Prevention . 2020. Preparing for COVID-19 in Nursing Homes. [Google Scholar]
  11. Champredon D., Najafi M., Laskowski M., Chit A., Moghadas S.M. Individual movements and contact patterns in a Canadian long-term care facility. AIMS Public Health. 2018;5:111–121. doi: 10.3934/publichealth.2018.2.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chu D.K., Akl E.A., Duda S., Solo K., Yaacoub S., Schünemann H.J., COVID-19 Systematic Urgent Review Group Effort (SURGE) Study Authors Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395:1973–1987. doi: 10.1016/S0140-6736(20)31142-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., Hernán M.A., Lipsitch M., Reis B., Balicer R.D. BNT162b2 mRNA Covid-19 vaccine in a Nationwide mass vaccination setting. N. Engl. J. Med. 2021 doi: 10.1056/NEJMoa2101765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. DeBiasi R.L., Delaney M. Symptomatic and asymptomatic viral shedding in pediatric patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): under the surface. JAMA Pediatr. 2020 doi: 10.1001/jamapediatrics.2020.3996. [DOI] [PubMed] [Google Scholar]
  15. Defence Research and Development Canada . 2020. COVID-19 Point Prevalence Map. [Google Scholar]
  16. Dhakal S., Klein S.L. Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J. Virol. 2019;93 doi: 10.1128/JVI.00797-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. ECDC Public Health Emergency Team, Danis K., Fonteneau L., Georges S., Daniau C., Bernard-Stoecklin S., Domegan L., O’Donnell J., Hauge S.H., Dequeker S., Vandael E., Van der Heyden J., Renard F., Sierra N.B., Ricchizzi E., Schweickert B., Schmidt N., Abu Sin M., Eckmanns T., Paiva J.-A., Schneider E. High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020. Eurosurveillance. 2020;25 doi: 10.2807/1560-7917.ES.2020.25.22.2000956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ferretti L., Wymant C., Kendall M., Zhao L., Nurtay A., Abeler-Dörner L., Parker M., Bonsall D., Fraser C. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020;368:eabb6936. doi: 10.1126/science.abb6936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fisman D., Lapointe-Shaw L., Bogoch I., McCready J., Tuite A. Failing our most vulnerable: COVID-19 and long-term care facilities in Ontario (preprint) medRxiv. 2020 doi: 10.1101/2020.04.14.20065557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Garnier-Crussard A., Forestier E., Gilbert T., Krolak-Salmon P. Novel coronavirus (COVID-19) epidemic: what are the risks for older patients? J. Am. Geriatr. Soc. 2020;68:939–940. doi: 10.1111/jgs.16407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gatto M., Bertuzzo E., Mari L., Miccoli S., Carraro L., Casagrandi R., Rinaldo A. Spread and dynamics of the COVID-19 epidemic in Italy: effects of emergency containment measures. Proc. Natl. Acad. Sci. 2020;117:10484–10491. doi: 10.1073/pnas.2004978117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Government of Canada . 2021. COVID-19 Vaccination in Canada - Vaccination Coverage. [Google Scholar]
  23. He X., Lau E.H.Y., Wu P., Deng X., Wang J., Hao X., Lau Y.C., Wong J.Y., Guan Y., Tan X., Mo X., Chen Y., Liao B., Chen W., Hu F., Zhang Q., Zhong M., Wu Y., Zhao L., Zhang F., Cowling B.J., Li F., Leung G.M. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 2020;26:672–675. doi: 10.1038/s41591-020-0869-5. [DOI] [PubMed] [Google Scholar]
  24. Hsu A., Lane N., Sinha S., Dunning J., Dhuper M., Kahiel Z., Sveistrup H. International Long-Term Care Policy Network; 2020. Report: Understanding the Impact of COVID-19 on Residents of Canada’s Long-Term Care Homes — Ongoing Challenges and Policy Responses. [Google Scholar]
  25. Iacobucci G. Covid-19: NHS staff must be tested weekly to keep services running, say MPs. BMJ. 2020 doi: 10.1136/bmj.m3804. [DOI] [PubMed] [Google Scholar]
  26. Ladhani S.N., Chow J.Y., Janarthanan R., Fok J., Crawley-Boevey E., Vusirikala A., Fernandez E., Perez M.S., Tang S., Dun-Campbell K., Evans E.W., Bell A., Patel B., Amin-Chowdhury Z., Aiano F., Paranthaman K., Ma T., Saavedra-Campos M., Myers R., Ellis J., Lackenby A., Gopal R., Patel M., Brown C., Chand M., Brown K., Ramsay M.E., Hopkins S., Shetty N., Zambon M. Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. EClinicalMedicine. 2020;26:100533. doi: 10.1016/j.eclinm.2020.100533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lauer S.A., Grantz K.H., Bi Q., Jones F.K., Zheng Q., Meredith H.R., Azman A.S., Reich N.G., Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 2020;172:577–582. doi: 10.7326/M20-0504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Li R., Pei S., Chen B., Song Y., Zhang T., Yang W., Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Science. 2020;368:489–493. doi: 10.1126/science.abb3221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Li X., Xu W., Dozier M., He Y., Kirolos A., Theodoratou E. The role of children in transmission of SARS-CoV-2: a rapid review. J. Glob. Health. 2020;10 doi: 10.7189/jogh.10.011101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lipsitch M., Kahn R. Interpreting vaccine efficacy trial results for infection and transmission (preprint) medRxiv. 2021 doi: 10.1101/2021.02.25.21252415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Liu M., Maxwell C.J., Armstrong P., Schwandt M., Moser A., McGregor M.J., Bronskill S.E., Dhalla I.A. COVID-19 in long-term care homes in Ontario and British Columbia. Can. Med. Assoc. J. 2020;192:E1540–E1546. doi: 10.1503/cmaj.201860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Miller T.E., Garcia Beltran W.F., Bard A.Z., Gogakos T., Anahtar M.N., Astudillo M.G., Yang D., Thierauf J., Fisch A.S., Mahowald G.K., Fitzpatrick M.J., Nardi V., Feldman J., Hauser B.M., Caradonna T.M., Marble H.D., Ritterhouse L.L., Turbett S.E., Batten J., Georgantas N.Z., Alter G., Schmidt A.G., Harris J.B., Gelfand J.A., Poznansky M.C., Bernstein B.E., Louis D.N., Dighe A., Charles R.C., Ryan E.T., Branda J.A., Pierce V.M., Murali M.R., Iafrate A.J., Rosenberg E.S., Lennerz J.K. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020;34:13877–13884. doi: 10.1096/fj.202001700RR. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ministry of Health . 2020. COVID-19 Outbreak Guidance for LongTerm Care Homes (LTCH) [Google Scholar]
  34. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull. 2020;25 doi: 10.2807/1560-7917.ES.2020.25.10.2000180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Moghadas S.M., Fitzpatrick M.C., Sah P., Pandey A., Shoukat A., Singer B.H., Galvani A.P. The implications of silent transmission for the control of COVID-19 outbreaks. Proc. Natl. Acad. Sci. 2020;117:17513–17515. doi: 10.1073/pnas.2008373117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Moghadas S.M., Shoukat A., Fitzpatrick M.C., Wells C.R., Sah P., Pandey A., Sachs J.D., Wang Z., Meyers L.A., Singer B.H., Galvani A.P. Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proc. Natl. Acad. Sci. 2020;117:9122–9126. doi: 10.1073/pnas.2004064117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Najafi M., Laskowski M., de Boer P.T., Williams E., Chit A., Moghadas S.M. The effect of individual movements and interventions on the spread of influenza in long-term care facilities. Med. Decis. Mak. 2017;37:871–881. doi: 10.1177/0272989X17708564. [DOI] [PubMed] [Google Scholar]
  38. Ontario Long Term Care Association . 2019. This is Long-Term Care 2019. [Google Scholar]
  39. Ouslander J.G., Grabowski D.C. COVID-19 in nursing homes: calming the perfect storm. J. Am. Geriatr. Soc. 2020;68:2153–2162. doi: 10.1111/jgs.16784. [DOI] [PubMed] [Google Scholar]
  40. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Poline J., Gaschignard J., Leblanc C., Madhi F., Foucaud E., Nattes E., Faye A., Bonacorsi S., Mariani P., Varon E., Smati-Lafarge M., Caseris M., Basmaci R., Lachaume N., Ouldali N. Systematic severe acute respiratory syndrome coronavirus 2 screening at hospital admission in children: a French prospective multicenter study. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Public Health Ontario . 2020. Enhanced Epidemiological Summary: COVID-19 in Long-Term Care Home Residents in Ontario – January 15, 2020 to June 1, 2020. [Google Scholar]
  43. Sanche S., Lin Y.T., Xu C., Romero-Severson E., Hengartner N., Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 2020;26:1470–1477. doi: 10.3201/eid2607.200282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sayampanathan A.A., Heng C.S., Pin P.H., Pang J., Leong T.Y., Lee V.J. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet. 2021;397:93–94. doi: 10.1016/S0140-6736(20)32651-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Shoukat A., Wells C.R., Langley J.M., Singer B.H., Galvani A.P., Moghadas S.M. Projecting demand for critical care beds during COVID-19 outbreaks in Canada. Can. Med. Assoc. J. 2020;192:E489–E496. doi: 10.1503/cmaj.200457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Stall N.M., Jones A., Brown K.A., Rochon P.A., Costa A.P. For-profit long-term care homes and the risk of COVID-19 outbreaks and resident deaths. Can. Med. Assoc. J. 2020;192:E946–E955. doi: 10.1503/cmaj.201197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Statistics Canada . 2020. Labour Force Characteristics by Sex and Detailed Age Group, Annual, Inactive. [DOI] [Google Scholar]
  48. U.S. Food and Drug Administration . 2020. Moderna COVID-19 Vaccine VRBPAC Briefing Document. [Google Scholar]
  49. Wang B., Li R., Lu Z., Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12:6049–6057. doi: 10.18632/aging.103000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wang J., Yang W., Pan L., Ji J.S., Shen J., Zhao K., Ying B., Wang X., Zhang L., Wang L., Shi X. Prevention and control of COVID-19 in nursing homes, orphanages, and prisons. Environ. Pollut. 2020;266:115161. doi: 10.1016/j.envpol.2020.115161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Webster P. COVID-19 highlights Canada’s care home crisis. Lancet. 2021;397:183. doi: 10.1016/S0140-6736(21)00083-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zhang K., Vilches T.N., Tariq M., Galvani A.P., Moghadas S.M. The impact of mask-wearing and shelter-in-place on COVID-19 outbreaks in the United States. Int. J. Infect. Dis. 2020;101:334–341. doi: 10.1016/j.ijid.2020.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zhang K., Shoukat A., Crystal W., Langley J.M., Galvani A.P., Moghadas S.M. Routine saliva testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers. Infect. Control Hosp. Epidemiol. 2021:1–5. doi: 10.1017/ice.2020.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material

mmc1.pdf (329.8KB, pdf)

Articles from Preventive Medicine are provided here courtesy of Elsevier

RESOURCES